Insiders who reported open-market trades in the last 12 months at the companies Erez Chimovits files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Erez Chimovits is a corporate insider, tracked as Director of ADARx Pharmaceuticals, Inc. (ADRX). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Erez Chimovits submitted recently?
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Erez Chimovits been buying or selling stock?
Recorded transactions: 5 open-market purchases ($49.99M) and 0 open-market sales across all tracked filings.
Erez Chimovits is Director of ADARx Pharmaceuticals, Inc. (ADRX). 6 SEC Form 4 filings on record going back to 2024, most recently on 30 September 2026. Most recent open-market trade: bought $1.05M of ADRX on 30 September 2026. Lifetime open-market purchases: $49.99M.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Erez Chimovits.
InsiderAlpha's records for Erez Chimovits go back to 2024: 6 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $10.00M (5 buys totaling $49.99M). The largest single buy on record is $30.00M of BRVE in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
